This was a Phase I , single-centre , randomised , double-blind , three-way crossover study during which subjects received three single doses of 1 g rectal suppositories ( containing 5 or 10 mg NRL001 or matching placebo ) or 2 g rectal suppositories ( containing 10 or 15 mg NRL001 or matching placebo ) on three separate dosing days .